Abstract-Angiotensin II (Ang II) has been previously shown to stimulate the extracellular signal-regulated kinase (ERK)1/2 and c-Jun N-terminal kinase (JNK) mitogen-activated protein (MAP) kinase family members. Little is known regarding the upstream signaling molecules involved in Ang II-mediated JNK activation. Ang II has been shown to activate the Janus kinase/signal transducer(s) and activator(s) of transcription (JAK/STAT) pathway, suggesting similarities to cytokine signaling. In response to cytokines such as interleukin-1 and tumor necrosis factor-␣, the p21-activated kinase (PAK) has been identified as an upstream component in JNK activation. Therefore, we hypothesized that PAK may be involved in JNK activation by Ang II in vascular smooth muscle cells (VSMCs). ␣PAK activity was measured by myelin basic protein phosphorylation in rat aortic VSMCs. In response to Ang II, ␣PAK was rapidly stimulated within 1 minute, with a peak (5-fold increase) at 30 minutes. ␣PAK stimulation preceded activation of JNK in VSMCs. Ang II-mediated activation of both ␣PAK and JNK was Ca 2ϩ dependent and inhibited by downregulation of phorbol ester-sensitive protein kinase C isoforms (by pretreatment with phorbol 12,13-dibutyrate) but not by pretreatment with GF109203X. Activation of both PAK and JNK was partially inhibited by tyrosine kinase inhibitors but not by specific Src inhibitors, suggesting regulation by a tyrosine kinase other than c-Src. Finally, introduction of dominant negative PAK markedly reduced the JNK activation by Ang II in both Chinese hamster ovary and COS cells stably expressing the Ang II type 1 receptor (AT1R). Our data provide evidence for ␣PAK as an upstream mediator of JNK in Ang II signaling and extend the role of Ang II as a proinflammatory mediator for VSMCs. (Circ Res. 1998;82:1272-1278.)
T he renin-angiotensin system has been implicated in several cardiovascular diseases, including hypertension, restenosis after balloon injury, atherosclerosis, and myocardial infarction. Ang II is the main effector of the reninangiotensin system and has previously been shown to promote growth and inhibit apoptosis, [1] [2] [3] [4] thus contributing to cardiac and vascular hypertrophy. The growth-promoting and antiapoptotic effects of Ang II depend on the regulation of transcription factors, which induce the expression of specific genes leading to protein synthesis, cell division, or inhibition of cell death pathways. Many of the signaling events relevant for these complex processes are mediated through activation of the MAP kinase family members ERK1/2 and JNK, which have been shown to be activated by Ang II. 5, 6 The MAP kinases activate transcription factors involved in the regulation of cell proliferation and differentiation as well as apoptosis, including c-Jun, Elk-1, and ATF2. 7 Activation of ERK1/2 and JNK by Ang II is mediated by the AT1R. 3, 8 The AT1R has been recently cloned and shown to belong to the seven transmembrane-spanning, G protein-coupled receptor family. 9, 10 The signal transduction events that link AT1R activation to the stimulation of ERK1/2 have been elucidated in recent years 11 ; however, the mechanisms leading to JNK activation are less well defined. 6 The JNK/stress-activated protein kinase members of the MAP kinase family have been shown to be stimulated by both inflammatory stimuli (eg, interleukin-1 and TNF-␣) and cellular stresses (eg, anisomycin, hyperosmolarity, and UV light). 12 The small G proteins Rac and Cdc42Hs are important upstream mediators of JNK activation because constitutively active mutants of these small GTPases enhance JNK activity, whereas dominant negative mutants block activation of JNK. 13, 14 A putative downstream component of Rac and Cdc42Hs in the signaling pathway leading to JNK activation is PAK, 15 which becomes activated on binding to GTP-bound Rac or Cdc42Hs. PAK has been implicated in the regulation of JNK by its ability to increase JNK activity when overexpressed 16 and to inhibit cytokine-induced JNK activity when a dominant negative PAK mutant is transfected into cells. 17 However, several other kinases that might substitute for PAK function have been implicated in JNK activation. First, members of the mixed-lineage kinase subfamily of serine/ threonine kinases have been shown to act downstream of Rac/Cdc42Hs and upstream of mitogen-activated protein kinase/extracellular signal-related kinase kinase1 (MEKK1) (dual leucine zipper-bearing kinase [DLK]) 18 or SEK1/MKK4 (SPRK). 19 Second, germinal center kinase (GCK), a member of a second family of Ste20-related kinases, has been shown to activate JNK when overexpressed. 20 Thus, multiple nonexclusive pathways may stimulate JNK. Because Ang II has recently been shown to stimulate the JAK/STAT pathway as well as JNK, Ang II exhibits similarities in signal events to cytokines such as interleukins, interferons, and TNF. In addition, physiologically, Ang II has cytokine-like properties, such as the ability to stimulate NADH oxidase in VSMCs, 21 increase TNF production by monocytes, 22 and regulate cell growth and apoptosis, 4 that in concert would promote inflammation.
In the present report, we identify ␣PAK as an upstream activator of JNK in VSMCs stimulated by Ang II. Activation of both PAK and JNK was Ca 2ϩ dependent and inhibited by downregulation of phorbol ester-sensitive PKC isoforms. Activation of both PAK and JNK was partially inhibited by tyrosine kinase inhibitors but not by specific Src inhibitors, suggesting that a tyrosine kinase other than c-Src also acts upstream of PAK and JNK in Ang II signaling.
Materials and Methods

Materials
Polyclonal ␣PAK (sc-881) antibody was purchased from Santa Cruz Biotechnology Inc. GST-c-Jun; glutathione-agarose; and antibodies to PAK-1-NT, PAK-2-NT, and PAK-3-NT were kindly provided by Kinetek Pharmaceuticals Inc. MBP, A23187, thapsigargin, anisomycin, and Ang II were purchased from Sigma Chemical Co. Genistein, tyrphostin 23, and BAPTA-AM were purchased from Calbiochem. Herbimycin A was purchased from Biomol. CP-118,556 (also referred to as PP1) was kindly provided by Pfizer Inc. [␥- 32 
Cell Culture
VSMCs were isolated from 200-to 250-g male Sprague-Dawley rats and maintained in DMEM supplemented with 10% bovine calf serum, as previously described. 5 Passage 8 to 15 VSMCs at 80% confluence were growth arrested by incubation in 0.4% calf serum for 24 hours before use. CHO cells stably transfected with AT1R were kindly obtained from Dr Kenneth Baker (Weis Center for Research) and maintained in F-12 medium supplemented with 20 mmol/L HEPES, 0.2 mg/mL G418, and 10% fetal calf serum. The COS-7 cells were transfected with the pcDNA3.1-AT1, and stably transfected cells were selected by G418. Cells were maintained in DMEM supplemented with 1 mmol/L sodium pyruvate, 0.2 mg/mL G418, and 10% fetal calf serum.
Immunocomplex MBP In-Gel Kinase Assay
Growth-arrested VSMCs were stimulated and cells were lysed with lysis buffer containing 10 mmol/L HEPES (pH 7.4), 0.1% Triton X-100, 5 mmol/L EGTA, 5 mmol/L EDTA, 50 mmol/L NaCl, 50 mmol/L NaF, 50 mmol/L sodium pyrophosphate, 1 mmol/L sodium orthovanadate, 10 g/mL leupeptin, and 1 mmol/L PMSF. Lysates were precleared by centrifugation, and protein concentration was measured by DC protein assay (Bio-Rad). ␣PAK antibody was added to equal amounts of protein per sample and incubated for 12 hours at 4°C. Antibody complexes were collected by addition of protein A-agarose for 3 hours. Precipitates were washed 5 times in cell lysis buffer, resuspended in SDS sample buffer, and boiled for 10 minutes. After centrifugation for 10 minutes at 10 000g, the supernatants were size fractionated by SDS-PAGE, and PAK activity was assayed by 32 P incorporation into MBP using an in-gel kinase assay as previously described. 
Transient Expression of Dominant Negative PAK and Tagged JNK
COS-AT1R and CHO-AT1R cells were cotransfected with plasmids encoding dominant negative PAK (pCMV6 M-PAK1-K299R) 17 and FLAG-tagged JNK1 (pcDNA3 M2-JNK1) with the use of LipofectAMINE (Life Technologies). Cells were allowed to recover after transfection for 24 hours in DMEM with 10% serum and were then serum starved for 24 hours before stimulation with Ang II. As a control vector for dominant negative PAK1, cells were transfected with pCMV-lacZ.
Densitometry and Statistical Analysis
For quantification of 32 P incorporation into MBP (PAK) or GST-cJun (JNK), autoradiographic films were scanned and analyzed by densitometry with NIH Image 1.59 software. Activation is presented as the fold increase over the respective control (meanϮSEM) based
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Results
Activation of JNK and PAK by Ang II in VSMCs
To determine whether Ang II stimulated JNK in VSMCs, cells were treated with 100 nmol/L Ang II, and JNK activity was measured by using GST-c-Jun as the substrate. In accordance with previous reports, 6, 8 Ang II stimulated JNK in VSMCs, with the onset of activity at 10 minutes and a peak at 30 minutes ( Figure 1 ). As a positive control, we used anisomycin, which has previously been shown to be a potent stimulator of JNK (Figure 1) . PAK has been identified as an upstream kinase of JNK that is stimulated by cytokines. To measure PAK activation by Ang II, PAK was immunoprecipitated from cells treated with 100 nmol/L Ang II, and an in-gel-kinase assay with MBP as the substrate was performed. PAK was activated by Ang II within 1 minute, with a peak at 30 minutes (5.2Ϯ1.6-fold increase) and sustained activation up to 60 minutes ( Figure  2 ). Similar results were obtained when a PAK immunocomplex in vitro kinase assay was performed with MBP as the exogenous substrate (data not shown). The dependence on Ang II concentration (1 nmol/L to 1 mol/L) for PAK activation in VSMCs was measured at 5 minutes. Ang II stimulated PAK in a dose-dependent manner, with maximal stimulation at 10 nmol/L (Figure 3 ).
␣PAK Is the Predominant PAK Isoform in VSMCs Stimulated by Ang II
Mammalian tissues contain at least 3 PAK isoforms. ␣PAK (PAK-1) is highly expressed in the brain, muscle, and spleen. ␥PAK (PAK-2, hPAK65) is ubiquitously expressed, and ␤PAK (PAK-3) is highly enriched in the brain. 23 The antibody sc-881 used in this study for immunoprecipitation is directed against ␣PAK but shows partial cross-reactivity against ␥PAK and ␤PAK. Therefore, we determined which PAK isoforms were expressed in VSMCs compared with other cell types known to express specific isoforms. Using isoform-specific PAK antibodies for Western blot analysis, we found that ␣PAK was the predominant isoform expressed in VSMCs (Figure 4) . ␤PAK was only weakly expressed in VSMCs, whereas ␥PAK was not expressed in VSMCs but was highly expressed in NIH-3T3 cells (Figure 4 ). Immunoprecipitation of ␤PAK and ␥PAK antibodies and subsequent Western blotting with ␤PAK and ␥PAK, respectively, confirmed these results, indicating low-level expression of ␤PAK only in VSMCs (data not shown). An MBP immunocomplex in vitro kinase assay with ␤PAK isoform-specific antibodies failed to show ␤PAK activation by Ang II (data not shown). Ang II has previously been shown to stimulate JNK in a Ca 2ϩ -dependent manner in liver epithelial cells 6 and cardiac myocytes. 8 Differing results for the PKC dependence of Ang II-mediated JNK activation were reported for these cell systems. Whereas JNK activation by Ang II was PKC independent in liver epithelial cells, 6 JNK activation was PKC dependent in cardiac myocytes. 8 The following experiments investigated the dependence of Ang II-mediated JNK and ␣PAK activation in VSMCs on Ca 2ϩ and PKC. Chelation of extracellular Ca 2ϩ only with 1 mmol/L EGTA did not affect ␣PAK activation by Ang II. We have recently shown that this protocol completely blocks Ca 2ϩ entry into VSMCs but has no effect on the rapid increase in Ca 2ϩ stimulated by Ang II. -free HBSS buffer (DMSO control in Figure 5 ) was smaller than after preincubation in DMEM supplemented with 0.4% fetal calf serum (eg, Figure 1) . Furthermore, BAPTA-AM pretreatment alone increased activity of JNK in VSMCs ( Figure 5A, lower panel) . This phenomenon has previously been reported for the activation of JNK 6 and has been interpreted as a stress-related or toxic effect of BAPTA-AM. 6 We next determined the effect of downregulation of phorbol ester-sensitive PKC isoforms on ␣PAK and JNK activation by Ang II and PMA. PMA alone (1 mol/L) activated ␣PAK and JNK Ϸ2-fold ( Figure 6A and 6B) compared with the 4-fold and 2.5-fold increases, respectively, with Ang II, indicating that signals in addition to PKC are required for full activation of ␣PAK and JNK. Downregulation of PKC by pretreatment with 1 mol/L PDBU, which inhibits the phorbol ester-binding PKC isoforms (PKC-␣, -␤, -␥, -␦, -⑀, -, and -) for 24 hours inhibited Ang II-and PMA-mediated activation of ␣PAK and JNK ( Figure 6A ). Pretreatment with 1 mol/L GF109203X for 10 minutes (an inhibitor of PKC-␣, -␤,-␥, -␦, and -⑀ 25 ) did not affect ␣PAK and JNK activation by Ang II (Figure 6A ), whereas PMAmediated ␣PAK and JNK activation was diminished. Interestingly, Eguchi et al 26 reported that Ang II-mediated activation of ERK1/2 in VSMCs could be inhibited by PMA pretreatment, whereas GF109203X had no effect on ERK1/2 activation. Because PDBU downregulation inhibited JNK activation but GF109203X had no effect, these findings suggest that the PKC isoforms involved in ␣PAK and JNK activation by Ang II in VSMC are most likely PKC-or -.
Activation of ␣PAK and JNK by Ang II Is Dependent on a Tyrosine Kinase Other Than Src
Tyrosine kinases have been implicated as upstream mediators of Ang II-induced JNK activation by the following findings. First, in GN4 liver epithelial cells JNK activation by Ang II could be inhibited by the tyrosine kinase inhibitor genistein. 6 Second, after comparing different liver epithelial cell lines, this same group of investigators reported a close correlation between activation of JNK and activation of the recently identified CADTK, which is the rat homolog of the human PYK2 tyrosine kinase. More recently, Brinson et al 27 showed that Ang II stimulated CADTK in VSMCs in a calcium-and PKC-dependent manner. We have previously demonstrated that Ang II activates the cellular tyrosine kinase c-Src and have shown that c-Src activation is critical for ERK1/2 stimulation by Ang II. 28 Moreover, v-Src has been implicated in activation of JNK in transiently transfected NIH-3T3 cells. 13, 18 Therefore, we determined the effect of different tyrosine kinase inhibitors on ␣PAK and JNK activation by Ang II. Pretreatment of VSMCs with 100 mol/L genistein for 1 hour (Figure 7) or with 100 mol/L tyrphostin 23 for 16 hours (data not shown) partially inhibited ␣PAK and JNK activation by Ang II. To address the role of c-Src more specifically, we investigated the effect of the tyrosine kinase inhibitor PP1, which has been reported to inhibit Src-family tyrosine kinases preferentially. 29 We have recently characterized the inhibitory effects of PP1 in vitro and found that c-Src, immunoprecipitated from VSMCs after Ang II stimulation, was inhibited by PP1, with an IC 50 of 1.32Ϯ0.27 mol/L. 30 Furthermore, we demonstrated that 10 mol/L PP1 inhibited ERK1/2 activation by Ang II. 28 To examine the effect of Src inhibition by PP1 on ␣PAK and JNK activation by Ang II, we pretreated VSMCs for 15 minutes and then measured ␣PAK and JNK activity. Neither ␣PAK nor JNK activation by Ang II was inhibited by 50 mol/L PP1 (Figure 7) . Furthermore, pretreatment of VSMCs with 1 mol/L herbimycin A, which is also thought to inhibit c-Src preferentially, had no effect on ␣PAK and JNK activation by Ang II (data not shown). These data indicate that c-Src is not the tyrosine kinase required for Ang II activation of JNK.
Dominant Negative PAK Inhibits the Activation of JNK by Ang II
To examine further whether ␣PAK is upstream of JNK in Ang II-mediated signaling, we introduced dominant negative PAK and FLAG-tagged-JNK into CHO-AT1R and COS-AT1R cells and measured activation of JNK. In both CHO-AT1R and COS-AT1R cells cotransfected with lacZ and FLAG-tagged-JNK, exogenous (FLAG tagged) JNK was activated by 100 nmol/L Ang II (Figure 8 ). In the CHO-AT1R cells cotransfected with dominant negative PAK and FLAG-tagged JNK, JNK activation by Ang II was completely inhibited. Similarly, in the COS-AT1R cells cotransfected with dominant negative PAK and FLAG-tagged JNK, JNK activation by Ang II was significantly inhibited. These results demonstrate that PAK is upstream of JNK in an Ang II-mediated signaling pathway.
Discussion
The major finding of this study is that Ang II-mediated activation of ␣PAK is required for stimulation of JNK in VSMCs. Our data further indicate that activation of PKC and a tyrosine kinase, together with mobilization of intracellular calcium, are required for Ang II-mediated ␣PAK and JNK activation. The following results suggest that ␣PAK acts upstream of JNK in Ang II signaling. Activation of ␣PAK preceded activation of JNK by Ang II in VSMCs. Activation of both ␣PAK and JNK appeared to be partially dependent on agonist-induced release of intracellular Ca 2ϩ . Downregulation of phorbol ester-sensitive PKC isoforms by PDBU or inhi- bition of PKC-␣, -␤,-␥, -␦, and -⑀ by GF109203X had similar effects on ␣PAK and JNK activation, in that PDBU pretreatment inhibited ␣PAK and JNK activation by Ang II, whereas pretreatment with GF109203X did not. Different tyrosine kinase inhibitors had the same inhibitory effects on ␣PAK and JNK activation, with inhibition by genistein and tyrphostin 23 and lack of inhibition by Src-selective tyrosine kinase inhibitors herbimycin A and PP1. Most importantly, in CHO and COS cells stably transfected with the AT1R, activation of JNK by Ang II was inhibited by transfection with dominant negative PAK. Although CHO and COS cells exhibited differences in signal transduction compared with VSMCs in several respects, they are a useful model system. In fact, we found that Ang II stimulated JNK (this study) and ERK1/2 (M. Ishida, unpublished observations, 1997) to the same magnitude and with a similar time course as VSMCs.
Activation of JNK has been reported to be positively and negatively regulated by PKC, depending on the cell type and stimulus investigated. Kudoh et al 8 demonstrated in cardiac myocytes that Ang II-stimulated JNK activation was inhibited by downregulation of PKC with PMA. In contrast, Zohn et al 6 reported that the Ang II-mediated JNK activation in GN4 liver epithelial cells was potentiated by downregulation of PKC by PMA pretreatment. Similarly, Cadwallader et al 31 reported that endothelin-1-mediated JNK activation in Rat-1 fibroblasts was negatively regulated by PKC. The Ca 2ϩ -dependent and phorbol ester-sensitive ␣PAK and JNK activation by Ang II observed in the present study suggests that a classic PKC isoform is involved in VSMCs. However, when we tested GF109203X, a PKC inhibitor that is thought to inhibit PKC-␣, -␤,-␥, -␦, and -⑀ preferentially, 25 we saw no inhibitory effect on ␣PAK or JNK activation by Ang II, whereas PMA-induced ␣PAK and JNK stimulation was inhibited ( Figure 6 ). These data suggest that novel PKC isoforms (PKC-and -) are upstream regulators of ␣PAK and JNK in Ang II signaling. Because these isoforms are Ca 2ϩ insensitive, the data suggest that the Ca 2ϩ dependence observed for ␣PAK and JNK is due to another mediator (eg, a calcium-dependent tyrosine kinase).
Tyrosine kinases implicated in JNK activation include PYK2 32 (also termed CADTK) 33 and Src. 13, 18 A role for CADTK is implied by the findings that overexpression of PYK2 stimulated JNK and that dominant negative mutants of Rac/Cdc42Hs effectively blocked PYK2-mediated JNK activation. 32 13, 18 Also, v-Src-mediated JNK activation was inhibited by coexpression of dominant negative Rac/Cdc42Hs 13 and dominant negative PAK, 18 placing Src upstream of Rac/Cdc42Hs and hence, of PAK. Recent data from our laboratory have shown that c-Src activation is critical for Ang II-induced ERK1/2 activation. 28 However, we found no evidence to support a role for c-Src in JNK activation by Ang II in VSMCs on the basis of studies with pharmacological inhibitors. While it is tempting to speculate that CADTK, PAK, and JNK constitute components of the same Ang II-dependent signaling pathway, future studies will be required to demonstrate this pathway in VSMCs.
The present data combined with recent findings from our laboratory regarding ERK1/2 activation 28,36 support the following model for Ang II-mediated ERK1/2 and JNK activation in VSMCs (Figure 9 ). ERK1/2 activation occurs via a Ca 2ϩ -independent pathway that involves c-Src and the atypical PKC isoform PKC-. In contrast, JNK activation occurs via a Ca 2ϩ -dependent pathway that involves a tyrosine kinase other than Src and a novel PKC isoform. We do not know the temporal sequence of activation of these upstream mediators for JNK. Important areas for future investigations include identification of the tyrosine kinase and PKC isoform involved in JNK activation. In addition, defining the roles of JNK and ERK1/2 in Ang II-mediated effects on VSMC function will be important. The present study, in combination with previous reports that Ang II stimulates the JAK/STAT pathway, 37 supports the emerging role of Ang II as a proinflammatory mediator for cardiovascular tissues. It is clear that understanding the in vivo consequences of Ang II cytokinelike actions may provide insights into the pathogenesis of cardiovascular disease. 38 which is an upstream regulator of Ras. 39 Activated Ras then interacts with PKC-, which we have identified as an upstream mediator of ERK1/2 stimulation. 36 B, Activation of a novel PKC isoform and a Ca 2ϩ -dependent tyrosine kinase (possibly CADTK) is required for stimulation of ␣PAK by Ang II. ␣PAK is a putative upstream regulator of JNK; however, kinases downstream of ␣PAK that mediate JNK activation by Ang II have not been identified so far.
